Diaceutics (LON:DXRX) Shares Down 0.6% - Should You Sell?

Key Points

• Diaceutics PLC shares fell 0.6% to GBX 161 ($2.14) with a significant drop in trading volume, down 65% from the average.
• Analysts have a consensus rating of "Buy" for Diaceutics with a target price of GBX 175, following recent adjustments from firms like Canaccord Genuity and Royal Bank Of Canada.
• The company's financials show a negative net margin of 10.90% and a negative return on equity of 7.15%, indicating ongoing challenges in profitability.

Diaceutics PLC (LON:DXRX - Get Free Report) shares dropped 0.6% on Tuesday . The company traded as low as GBX 160 ($2.13) and last traded at GBX 161 ($2.14). Approximately 51,107 shares traded hands during mid-day trading, a decline of 65% from the average daily volume of 148,036 shares. The stock had previously closed at GBX 162 ($2.16).

Analysts Set New Price Targets

A number of research firms have recently commented on DXRX. Canaccord Genuity Group reiterated a "buy" rating and set a GBX 180 price target on shares of Diaceutics in a report on Tuesday, July 22nd. Royal Bank Of Canada cut their price target on shares of Diaceutics from GBX 195 to GBX 185 and set an "outperform" rating on the stock in a report on Thursday, July 10th. Three analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of GBX 175.

Diaceutics Trading Down 0.6%

The company has a market cap of £136.23 million, a P/E ratio of -8,944.44 and a beta of 0.58. The stock's 50-day moving average is GBX 147.82 and its two-hundred day moving average is GBX 131.72. The company has a debt-to-equity ratio of 0.39, a current ratio of 4.85 and a quick ratio of 9.92.

Diaceutics (LON:DXRX - Get Free Report) last issued its quarterly earnings data on Tuesday, September 23rd. The company reported GBX (2.84) earnings per share for the quarter. Diaceutics had a negative net margin of 10.90% and a negative return on equity of 7.15%. As a group, equities research analysts predict that Diaceutics PLC will post 1.0107919 earnings per share for the current fiscal year.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.